TY - JOUR
T1 - Antiretroviral drugs in development. A report from HIV DART 2008
T2 - Frontiers in drug development for antiretroviral therapies
AU - Temesgen, Zelalem
PY - 2009/4/1
Y1 - 2009/4/1
N2 - HIV DART 2008, Frontiers in Drug Development for Antiretroviral Therapies, was held on 9 - 12 December 2008 in Puerto Rico. The stated purpose of this biannual international meeting is to assemble clinicians, researchers and basic scientists together to advance the knowledge of the ongoing drug development processes in antiretroviral research. However, there were also presentations of thematic reviews of clinical topics such as prevention and drug resistance; HIV therapy in developing countries; and HIV/hepatitis and other coinfections. This report focuses on the main theme of the conference, the antiretroviral drug development pipeline. The author is solely responsible for the selection of topics and presentations to be included in this report.
AB - HIV DART 2008, Frontiers in Drug Development for Antiretroviral Therapies, was held on 9 - 12 December 2008 in Puerto Rico. The stated purpose of this biannual international meeting is to assemble clinicians, researchers and basic scientists together to advance the knowledge of the ongoing drug development processes in antiretroviral research. However, there were also presentations of thematic reviews of clinical topics such as prevention and drug resistance; HIV therapy in developing countries; and HIV/hepatitis and other coinfections. This report focuses on the main theme of the conference, the antiretroviral drug development pipeline. The author is solely responsible for the selection of topics and presentations to be included in this report.
UR - http://www.scopus.com/inward/record.url?scp=67649580218&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649580218&partnerID=8YFLogxK
U2 - 10.1517/13543780902806418
DO - 10.1517/13543780902806418
M3 - Article
C2 - 19335283
AN - SCOPUS:67649580218
SN - 1354-3784
VL - 18
SP - 549
EP - 553
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
IS - 4
ER -